



BioScience under the Big Sky



February, 2019

QUICK LINKS

[Member News](#)

[Montana / Universities News](#)

[Industry News](#)

[Employment and Funding](#)

[What's Happening?](#)

[Events Calendar](#)

[Classifieds](#)

[Join our mailing list](#)

Welcome!



*Please Join us in Welcoming
New Member:*

Kelli Strother MS

[Be sure to Like Us on Facebook](#)



Montana BioScience Alliance's
2017 Directory,
[Click Here!](#)

MEMBER NEWS



DermaXon received a Phase 1 STTR Grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for ichthyosis.

June 2018

This award titled "Topical selective T-type blockers for the treatment of neuropathic pain" provides critical support of a research project which examines the efficacy of DermaXon's technology platform for the treatment of peripheral neuropathy. [Continue Reading](#)



SiteOne Therapeutics Receives NIH Grant to Support the Development of Novel Therapeutics to Treat Ocular Pain

September 25, 2018

Potential applications in pain associated with ocular surgery, injury, and Dry Eye Syndrome

BOZEMAN, Montana, Sept. 25, 2018 /PRNewswire/ -- SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, today announced the company has been awarded a \$1.4 million, two-year, Phase 2 SBIR grant from the National Eye Institute (NEI), a member of the US National Institutes of Health (NIH). The award will be used to initiate IND-enabling studies for SiteOne's Ocular NaV1.7 Program for pain associated with ocular surgery, injury and disease, such as Dry Eye Syndrome. This is the third Phase 2 SBIR grant that SiteOne has received from the NIH, the first having been awarded in September 2014 to support the discovery and development of selective inhibitors of NaV1.7 as therapeutics for acute and chronic pain. [Continue Reading](#)



Golden Helix Looks Ahead After Receiving NIH Grant For Structural Variation Detection

October 16, 2018

When Andreas Scherer took over as the CEO and president of Golden Helix in April 2013, he knew it was time for the company to shift from a research focus to a more clinical focus. With his Ph.D. in computer science, a master bioinformatics, and international business experience, Scherer was uniquely qualified to implement Golden Helix's expansion into the clinical space. The company launched its first clinical product in 2014 and a new product every six months or from then on out. This September, the Golden Helix celebrated its 20th anniversary and announced another grant from the



Xtant Medical Announces Appointment of Chief Operations Officer

Belgrade, MT Jan 11, 2019 (Globe Newswire)

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the appointment of Ronald Berlin as Vice President & Chief Operations Officer, effective January 1, 2019. Mr. Berlin will report to Michael Mainelli, Xtant's Interim Chief Executive Officer. [Continue Reading](#)

Amgen's once-dismissed osteoporosis drug Evenity 'back in the game' after rosy FDA panel vote

Jan 16, 2019

If you thought Amgen osteoporosis candidate Evenity (romosozumab) was down for the count, think again. After an overwhelmingly positive 18-1 vote in favor of approval from an FDA advisory panel Wednesday afternoon, the drug is "back in the game," as Jefferies analyst Michael Yee put it in a note to clients. Asked to vote on whether the overall risk/benefit profile of the prospect was acceptable to support its approval in postmenopausal women with osteoporosis at high risk for fracture, 16 experts voted yes; two voted yes, but with a different indication; and one voted no. [Continue Reading](#)



Missoula's Inimmune receives \$600K to develop novel treatments for seasonal allergies

Dec 13, 2018

Missoula-based Inimmune Corp. has received a nearly \$600,000 federal grant to identify and advance novel treatments for seasonal allergies. In an announcement Wednesday, the biotechnology firm said the two-year project will be led by Dr. Juhienah Khalaf, a medicine chemist at Inimmune. The \$592,624 Small Business Innovation Research contract was awarded by the National Institute for Allergy and Infectious Diseases. Earlier this year, Khalaf and Inimmune received another Small Business Innovation Research grant to develop treatments for upper respiratory tract infections. Already, Inimmune researchers have completed that grant's milestones and have applied for Phase II funding. [Continue Reading](#)

MRI Director Secures \$2M Dollar Grant

McLaughlin Research Institute Director Dr. Mike Kavanaugh recently received a five year, \$2.2M dollar grant from the National Institutes of Health to investigate how brain levels of the amino acid D-serine are regulated by a transporter known as SLC1A4, and how mutations in the human SLC1A4 gene cause neurological disease. This research involves studies of the linkage between SLC1A4 and N-methyl-D-aspartate receptors, receptors on nerve cells that play a critical role in triggering learning and memory. [Continue Reading](#)



Award made to Montana State University & Collaborating Institutions

An award is made to Montana State University and collaborating institutions to support the acquisition of a new 200kV cryo-electron microscopy system. The last decade has seen a revolution in cryo-electron microscopy (cryo-EM). With increasing frequency, single particle analysis (SPA) is providing cryo-EM maps at resolutions on par with X-ray crystallography, resulting in atomic models for a growing number of macromolecular assemblies - ribosomes, transcription complexes, proteasomes, viruses, integral membrane proteins and CRISPR/Cas targeting complexes - all directly from cryo-EM data. [Continue Reading](#)



Grant Allows UM to Expand Neuroscience Education Across Multiple Colleges

January 28, 2019

UM News Service
MISSOULA

- The University of Montana's mission to shape agile learners will take a step forward thanks to a \$300,000 grant from the W. M. Keck Foundation.

The grant will help UM faculty members in neuroscience, literature, psychology, philosophy and languages create courses with neuroscience themes for both science and non-science students. This new undergraduate curriculum - which builds on UM's growing neuroscience major

- stresses the impact of fast-evolving brain science on our understanding of a wide range of human experiences, including literature, history, art, language and education. [Continue Reading](#)



Pascal Biosciences and the University of Washington Enter Into Exclusive License Agreement to Develop Cannabinoid-based Medicine for Cancer

October 30, 2018 08:00 ET | Source: Pascal Biosciences Inc.

* Program Developed in Lab of Renowned Cannabis Researcher Dr. Nephi Stella-

* Lead Candidate for Glioblastoma to Begin Clinical Testing in 2019

VANCOUVER, B.C. and SEATTLE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) ("Pascal" or the "Company"), a drug discovery and development company, is pleased to announce that the Company has entered into an exclusive license agreement with the University of Washington (UW) in Seattle to develop a cannabinoid-based product for the treatment of glioblastoma multiform and brain metastases. The program, developed in the lab of renowned cannabis researcher Dr. Nephi Stella, founder and co-director of the UW Center for Cannabis Research, includes a lead therapeutic, ST-403. Pascal plans to begin human clinical studies of ST-403 in 2019.

[Continue Reading](#)



Eyes of CJD Patients Show Evidence of Prions

Finding Could Help Early Diagnosis, Raise Concern for Eye Exams and Transplants

November 20, 2018

National Institutes of Health scientists and their colleagues have found evidence of the infectious agent of sporadic Creutzfeldt-Jakob disease (CJD) in the eyes of deceased CJD patients. The finding suggests that the eye may be a source for early CJD diagnosis and raises questions about the safety of routine eye exams and corneal transplants. Sporadic CJD, a fatal neurodegenerative prion disease of humans, is untreatable and difficult to diagnose. [Continue Reading](#)

ScienceDaily®

Test detects protein associated with Alzheimer's and CTE

Findings could lead to early diagnosis, better treatment studies

December 20, 2018

NIH/National Institute of Allergy and Infectious Diseases

An ultrasensitive test has been developed that detects a corrupted protein associated with Alzheimer's disease and chronic traumatic encephalopathy (CTE), a condition found in athletes, military veterans, and others with a history of repetitive brain trauma. This advance could lead to early diagnosis of these conditions and open new research into how they originate. [Continue Reading](#)



Institute of **Translational** Health Sciences

ACCELERATING RESEARCH. IMPROVING HEALTH.

New year, new federal policies for clinical & translational research (2019)

Posted on January 22, 2019

Many researchers are tucking in to finish their first National Institutes of Health (NIH) grant proposals or IRB applications of the year. A number of changes to federal regulations and NIH policies relevant to clinical and translational research take effect in January 2019.

REVISING THE RULE FOR HUMAN RESEARCH PROTECTIONS

The Common Rule has been a fundamental part of clinical and translational research for decades. This set of regulations aims to provide protections for individuals participating in research conducted, funded, or regulated by several federal agencies. With so much university research funded by federal sources, institutional human research protection programs (HRPP) apply the Common Rule to almost all the research they review. [Continue Reading](#)

NIH scientists explore tick salivary glands as tool to study virus transmission and infection

Tuesday, January 29, 2019

The salivary glands of some tick species could become important research tools for studying how viruses are transmitted from ticks to mammals, and for developing preventive medical countermeasures. Tick salivary glands usually block transmission, but a new study conducted by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health focuses on the role of salivary glands in spreading flaviviruses from black-legged ticks (*Ixodes scapularis*) to mammals. The new study, published in the journal *mBio*, advances the researchers' work published in 2017 that established cultured tick organs as a model for flavivirus infection. [Continue Reading](#)

Geneticists use CRISPR to cut toxic protein out of the aging equation

Thursday, February 21, 2019

There is much we don't understand about the aging of the human body, but working with what we do know researchers continue to uncover potential new ways to slow down the process. Among them is a team of genetic scientists at the Salk Institute, which has developed a new therapy using the CRISPR/Cas9 tool that has greatly boosted the lifespan of rapidly aging mice. [Continue Reading](#)

EMPLOYMENT AND FUNDING OPPORTUNITIES



MONTANA
HEALTHCARE
FOUNDATION

Job Opening: Program Assistant Join our team!

The Montana Healthcare Foundation is pleased to announce the opening of a Program Assistant position. This is an opportunity for an innovative professional to join a creative, growing organization with a permanent endowment to support health improvement in Montana. This is a tactical support role for our Program team, which is responsible for implementing the Foundation's strategic programming. Idea candidates will connect with our work to improve the health and well-being of all Montanans.

[Click here to learn more!](#)

GSK Hamilton

The Hamilton site is located on a 35-acre campus in the heart of the scenic Bitterroot Valley of western Montana. It started in 1981 as Ribic ImmunoChem Research, Inc., a company focused on research and development of vaccine components capable of stimulating the immune system. GSK purchased the site in 2005 to acquire its proprietary adjuvant technology which is used to help make vaccines more effective. GSK Hamilton currently employs over 185 professionals and is expanding its job base with the addition of a new adjuvant manufacturing facility.

To review current openings at the GSK Hamilton (GlaxoSmithKline) site please go to

<https://www.gsk.com/en-gb/careers/careers-search/?q=&bu=&r=usa&city=hamilton&et=&prog=>

WHAT'S HAPPENING?

At the Montana BioScience Alliance Annual meeting in Missoula, July 24, 2018, election of officers was held. Officers elected: Stan Abel, President/Chairman, Ron Zook, Vice-chair, Chris Aageson, Secretary, and Carol Beam, Treasurer. Reelected board members are: Mark Jutila, Carol Beam, Teresa Gunn, Ron Zook, David Crum, and John Delaney. Diane Duin has resigned from the board and moved to South Dakota.

A Montana BioScience Alliance meeting was held in Helena on February 13, 2019.. The group heard an update from Deputy Attorney General Jon Bennion on opioid abuse and prescription drug registry. Aidan Myhre presented an update on current legislation affecting the industry. And Derek Oestreicher from the Insurance Commissioner's office updated on PBMs and Transparency legislation. We also heard from Brigitta Miranda-Freer regarding the World Trade Center and Montec and from Adam Friedman regarding the Innovation Campus in Bozeman. Following the meeting a well attended Legislative Reception was held at the Holter Museum of Fine Art.

Tim Braun, Swan Valley Medical, represented the Montana BioScience Alliance at the 2019 SCCM Critical Care Congress February 17-20 in San Diego.

We are looking forward to the BIO International Convention in Philadelphia, June 3-6 2019 and encourage folks to join us.

EVENT'S CALENDAR



BIO Fly-In 2019: Get your voice heard on Capitol Hill

Join other Montana biotech and life science leaders at this year's BIO Fly-In to Washington, D.C. happening **April 3-4**. [Registration is now open](#) (closing March 4). Organizers suggest both registering and securing your hotel in the block of rooms at the Capitol Hilton ASAP. Here are all the handy resources:

- [Registration Link for Fly-In](#)
- [Hotel Block and Information Link](#)
- [Agenda / Schedule of events Link](#)

For more Info about the Fly-In, please [VISIT THIS FLY-IN PAGE](#).

2019 Life Science Innovation Northwest



APRIL 24 - 25, 2019

WASHINGTON STATE CONVENTION CENTER

The Pacific Northwest's biggest annual life science conference. A two-day event bringing together

investors, public and private life science organizations, research institutions, scientists, entrepreneurs, and the global health community to discuss and feature some of the most compelling technology breakthroughs of our time. [Click Here to Learn More!](#)

Save the Date for BIO 2019: Philadelphia, PA June 3-6, 2019



Day by day, bit by bit, cutting-edge research institutes, promising startups and global companies in a wide array of biotechnology and related fields take on big, global challenges. These innovative and globally important advances in biotech begin with one meeting, one theory, one trial, one breakthrough. You make it happen. Because of you small, local initiatives can have a global impact. The innovative and globally important advances in biotech-new drugs, alternate fuel sources or more nutrient-rich food sources-start with one. The "It Starts With One" theme highlights the game changing impact of the small, daily efforts of BIO attendees.

The key benefits of attending the 2019 BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry thought-leaders with over 500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 67 countries.

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. [Click Here to Learn More!](#)



The Rocky Mountain Life Science Investor & Partnering Conference returns to Vail, CO **September 4-5, 2019** to bring together leading investors and strategic partners from across the U.S. and the region's top life science companies to cultivate partnerships and source investment opportunities in the areas of medical device, diagnostic, biotech, pharma and digital health.

Wednesday, September 4 5:30-7:30pm - Welcome Reception

Thursday, September 5 - All Day Conference & Partnering

[Click Here to Learn More!](#)

CLASSIFIEDS



Through its partnership with the Biotechnology Innovation Organization (BIO), the international organization that represents the biotechnology industry, MBA offers its members the opportunity to take advantage of several of the BIO Business Solutions® programs, as listed below. Click on the company name to learn more about an individual program.

There is no fee for MBA members to utilize any of the programs and BIO membership is not a requirement for MBA members.

New for 2019! Scientific research services!



scientist.com

Montana Bioscience Alliance's newest savings program is Scientist.com, the online marketplace for outsourced

scientific services and products, offering custom research services through thousands of pre-qualified suppliers, Montana BioScience Alliance member benefits include:

- Savings through competitive price quotes from multiple suppliers
- Free marketplace registration
- Access to the world's largest commercial CRO network: 2,600+ prequalified, registered suppliers
- Vendor consolidation: all contracting and billing managed by Scientist.com
- [Click here to learn more!](#)

[UPS-Shipping Services](#)

[American Laboratory Trading, Inc. \(ALT\)](#)

Premium Refurbished Laboratory Equipment and Asset Management Services

[VWR International](#)

Laboratory Supplies, Equipment & Chemicals

[Chubb](#)

Property and Casualty Insurance, Clinical Trials Liability Insurance, Errors and Omissions Liability Insurance, Professional Liability Insurance, Products Liability Insurance

[Office Depot](#)

Office Supplies, Furniture, Equipment and Technology Products/Design, Print, and Ship Services

[Business Wire](#)

News & Multimedia Distribution, Social Media Monitoring, Financial Disclosure Services

[Aon Risk Solutions](#)

Executive Liability Insurance

[UniFirst](#)

Workwear Services

[UniClean](#)

Cleanroom Services

[Clean Harbors](#)

Environmental Services

[ShareVault](#)

Secure Document Sharing & Virtual Data Room Solutions

[Airgas](#)

Packaged & Bulk Gases

[Humboldt](#)

Moving and Storage

[Nikon Instruments](#)



The Montana Bioscience Alliance serves as a hub for Montana's biotechnology companies, entrepreneurs, laboratories, hospitals, clinics and universities to commercialize, grow and sustain globally competitive bioscience companies -- ultimately to create high-quality jobs and economic opportunity in Montana.

Sharon Peterson
Executive Director
Montana BioScience Alliance
sharonpeterson@bresnan.net